Shanghai Hengrui Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS17
PHASE 3 / 2-33
RECRUITING15
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO17%
Delay Index: of 12 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shanghai Hengrui Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SHR-1501 NCT05410730 |
P1/2 | Recruiting | High-risk NMIBC | 150 | 2025-05 |
| SHR-A2102 for Injection NCT06738251 |
P3 | Recruiting | Advanced Urothelial Carcinoma | 402 | 2026-07 |
| SHR-A2102 for Injection NCT06512051 |
P1/2 | Recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 248 | 2026-10 |
| SHR-A2102 NCT07229729 |
P2 | Recruiting | Non-small Cell Lung Cancer | 300 | 2026-10 |
| SHR-7787 injection NCT06605222 |
P1/2 | Recruiting | Advanced Solid Tumors | 201 | 2026-12 (+4 mo) |
| SHR-4602 NCT06704828 |
P2 | Not yet recruiting | Advanced Solid Tumors | 20 | 2027-04 |
| SHR-A2102 NCT06639347 |
P1/2 | Recruiting | Advanced Urothelial Carcinoma | 90 | 2027-05-31 |
| SHR-A1904 NCT06649292 |
P3 | Recruiting | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 524 | 2027-09-20 |
| HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine NCT07296341 |
P1/2 | Recruiting | Locally Advanced or Metastatic Pancreatic Cancer With | 60 | 2027-10 |
| SHR-7367 Injection NCT07229586 |
P1/2 | Recruiting | Solid Tumor | 100 | 2027-12 |
| SHR-1501, Adebrelimab NCT07073534 |
P1/2 | Recruiting | Patients With Advanced or Metastatic Malignant Tumors | 203 | 2027-12 |
| SHR-A2102 NCT06895928 |
P2 | Recruiting | Advanced Solid Tumors | 400 | 2028-12 |
| SHR-7787 Injection NCT07268040 |
P2 | Recruiting | Malignant Solid Tumors | 400 | 2028-12 |
| SHR-7787 Injection NCT07798947 |
P2 | Recruiting | Limited-stage Small-cell Lung Cancer | 120 | 2028-12 |
| SHR-9839 for Injection NCT06474455 |
P1/2 | Recruiting | Advanced Solid Tumors | 156 | 2029-06 (+36 mo) |
| HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection NCT07900789 |
P3 | Not yet recruiting | Systemic Treatment-naïve Pancreatic Cancer | 825 | 2030-11-30 |
| SHR-A2102 NCT06417554 |
P1/2 | Recruiting | Advanced Solid Tumors | 80 | 2031-12-31 (+54 mo) |